Editas Medicine, Inc.EDIT
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · editasmedicine.com
Editas Medicine is a clinical-stage genome editing company developing CRISPR-based medicines, with in vivo programs targeting haematologic diseases including sickle cell disease and beta-thalassemia.
Key ratios
FCF / Sales
-256.5%TTM
2025
-409.3%2024
-678.1%2023
-175.2%
Net margin
-157.3%TTM
2023
-196.1%
ROA
-23.3%TTM
2025
-23.5%2024
-35.5%2023
-20.9%
ROE
-118.8%TTM
2025
-198.1%2024
-98.1%2023
-43.2%
Revenue growth
20.8%TTM
2025
25.4%2024
-58.6%2023
296.3%
Recent news
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Track EDIT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer